← Patent-cliff monitor small molecule TRUSELTIQ INFIGRATINIB PHOSPHATE
Loss of exclusivity December 2034 latest FDA-listed patent expiry
Company HELSINN HEALTHCARE SA
Drug detail Brand name TRUSELTIQ Active ingredient INFIGRATINIB PHOSPHATE Strength 100MG Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval May 2021 Marketing status DISCN
Listed patents Patent Expires Type 10278969 December 2034 product 11160804 December 2034 product 8552002 August 2029 substance, product 9067896 August 2028 substance
Regulatory exclusivity Code Expires ODE-353 May 2028 NCE May 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.